Dyne Therapeutics (DYN) Capital Expenditures (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Capital Expenditures of -$4.6 million for Q2 2026, down 7766.67% year-over-year from $60000.0 in Q2 2025, and down 2181.45% quarter-over-quarter from $221000.0 in Q1 2026.
Dyne Therapeutics (DYN) Capital Expenditures (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Capital Expenditures for 8 consecutive years, with -$4.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Capital Expenditures fell 7766.67% year-over-year to -$4.6 million; the TTM figure through Jun 2026 stood at $13.4 million (up 464.37% YoY), while the FY2025 annual figure was $18.8 million, up 690.82% from the prior year.
- Capital Expenditures retreated to -$4.6 million in Q2 2026 per DYN's latest filing, from $221000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $17.7 million in Q3 2025 and bottomed at -$4.6 million in Q2 2026.
- Historically, Capital Expenditures has averaged $1.2 million across 5 years, with a median of $253000.0 in 2024.
- Annual changes were most pronounced in 2025 — Capital Expenditures jumped 6915.42% — and 2026, when it plunged 7766.67%.
- Dyne Therapeutics' Capital Expenditures stood at $519000.0 in 2022, then slumped by 84.2% to $82000.0 in 2023, then soared by 1210.98% to $1.1 million in 2024, then surged by 1551.07% to $17.7 million in 2025, then sank by 125.92% to -$4.6 million in 2026.
- Business Quant data shows DYN's Capital Expenditures at -$4.6 million in Q2 2026, $221000.0 in Q1 2026, and $17.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | -4.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.60 Mn |
| Jun 30, 2026 | -4.60 Mn |
| Mar 31, 2026 | 221,000.00 |
| Mar 31, 2026 | 221,000.00 |
| Sep 30, 2025 | 17.75 Mn |
| Sep 30, 2025 | 17.75 Mn |
| Jun 30, 2025 | 60,000.00 |
| Jun 30, 2025 | 60,000.00 |
| Mar 31, 2025 | 981,000.00 |
| Mar 31, 2025 | 981,000.00 |
| Dec 31, 2024 | 1.08 Mn |
| Dec 31, 2024 | 1.08 Mn |
| Sep 30, 2024 | 253,000.00 |
| Sep 30, 2024 | 253,000.00 |
| Jun 30, 2024 | 857,000.00 |
| Jun 30, 2024 | 857,000.00 |
| Mar 31, 2024 | 191,000.00 |
| Mar 31, 2024 | 191,000.00 |
| Dec 31, 2023 | 82,000.00 |
| Dec 31, 2023 | 82,000.00 |